Potential synergistic benefits in reducing inflammation and improving lung function could be achieved through combination therapies targeting multiple aspects of COPD, including but not limited to NETosis and cGAS/TLR9 pathways. This evidence concerns the gene TLR9 and chronic obstructive pulmonary disease.